Total Funding
61
47
Total FundingSeries B raised
Growth Score 61 in past quarter
-2 pts
Heat Score 47 in past quarter
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
66985
Proniras focuses on development of a new parenteral medical countermeasure (MCM) to treat seizures and brain injury.
- Thong Le: CEO & DirectorPast Role: Accelerator Life Science Partners, President & CEO
- Christopher Toombs: Co-Founder and Chief Scientific OfficerPast Role: Faraday Pharmaceuticals, Founder & Chief Scientific Officer
About the Company
Proniras Corp is an operator of a biomedical company intended to develop drugs. The company's biomedical service has already demonstrated preclinical efficacy in treating nerve agent-induced seizures, as well as in studies of rodents exposed to the chemical weapon soman, which is more toxic than sarin gas, enabling medical researchers to
continue their research work and discover drugs.
It was founded in 2016 and is headquartered in Seattle, Washington.